Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Olaptesed Pegol (NOX-A12) with Pembrolizumab and Chemotherapy in Microsatellite-Stable Metastatic Pancreatic Cancer
2021-001963-25Phase 2Terminated
- Sponsor
- TME Pharma
- Start
- Dec 2021
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaptesed pegol in pancreatic cancer (PC) (2 arms), sponsored by TME Pharma. Primary endpoint: Disease Control Rate at 6 Weeks. Started Dec 2021; status: terminated.
02
Drugs
olaptesed pegol
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2021-001963-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001963-25.